ERNANasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as ERNAW
Ernexa Therapeutics Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$1.98−0.11 (-5.26%)
Close on Oct 19, 2026
- Market cap
- $2.34M
- P/E (TTM)
- –
- Dividend yield
- –
Ernexa Therapeutics Inc. revenue by segment
By business segment
By product or service
| Revenue | TTM Q4 20 | TTM Q3 20 | TTM Q2 20 | TTM Q1 20 | TTM Q4 19 | TTM Q3 19 | TTM Q2 19 | TTM Q1 19 | TTM Q4 18 | TTM Q3 18 | TTM Q2 18 | TTM Q1 18 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Subscription Revenue [Member] | $4.88M | $6.70M | $9.37M | $12.44M | $14.28M | $15.28M | $15.56M | $15.80M | $16.03M | $16.32M | $16.60M | $16.79M | 84.2% | -65.8% |
| Other Revenue [Member] | $492.00K | $1.13M | $1.93M | $2.76M | $3.18M | $3.31M | $3.30M | $3.49M | $3.72M | $3.72M | $3.68M | $3.75M | 8.5% | -84.5% |
| Hardware Revenue [Member] | $426.00K | $1.96M | $1.59M | $2.16M | $2.35M | $1.97M | $3.12M | $3.12M | $3.59M | $2.67M | $1.63M | $1.26M | 7.3% | -81.9% |
By region
| Revenue | TTM Q4 20 | TTM Q3 20 | TTM Q2 20 | TTM Q1 20 | TTM Q4 19 | TTM Q3 19 | TTM Q2 19 | TTM Q1 19 | TTM Q4 18 | TTM Q3 18 | TTM Q2 18 | TTM Q1 18 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States [Member] | $5.48M | $9.40M | $12.40M | $16.74M | $19.15M | $19.89M | $21.30M | $21.72M | $22.65M | – | – | – | 94.5% | -71.4% |
| Canada [Member] | $320.00K | $393.00K | $496.00K | $627.00K | $653.00K | $666.00K | $677.00K | $683.00K | $682.00K | – | – | – | 5.5% | -51.0% |
From the segment and revenue-disaggregation notes of Ernexa Therapeutics's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.